Clinical Trials Sponsored by Otsuka America Pharmaceutical

Total 676 results

Otsuka America Pharmaceutical

Completed

POCone-UBiT-IR300 Pediatric Comparison Study

Bacterial Infection Due to Helicobacter Pylori (H. Pylori)

United States
Otsuka America Pharmaceutical

Completed

Study for the Treatment of Crohn's Disease With Adacolumn

Crohn's Disease

United States, Canada
Otsuka America Pharmaceutical

Completed

Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon

Raynaud's Disease

United States
Otsuka America Pharmaceutical

Completed

Study for the Treatment of Ulcerative Colitis With Adacolumn

Ulcerative Colitis

United States, Canada
Otsuka America Pharmaceutical

Completed

Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon

Raynaud's Disease

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode

Bipolar Disorder

United States, Puerto Rico
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Study of Aripiprazole in Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

Bipolar I Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole in Patients With Acute Mania

Bipolar Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Schizophrenia Trial of Aripiprazole

Schizophrenia

Austria, United Kingdom, France, Spain, Sweden, Czech Republic, Denmark, Finland, Germany
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in Patients With Bipolar I Disorder

Bipolar Disorder

France, Portugal, Spain, Italy, Germany, South Africa, United Kingdom, United States, Russian Federation, Poland, Czech Republic, Hungary, Netherlands, Estonia, Australia, Bulgaria, Switzerland
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Withdrawn

A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

Bipolar Disorder

United States, India
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania

Bipolar Disorder

United States, South Africa, Brazil, Russian Federation, France, Czechia, Croatia, India, Bulgaria
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

Autistic Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)

Behavioral Symptoms | Autistic Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

Behavioral Symptoms | Autistic Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode

Bipolar Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia

Dementia | Alzheimer's Disease

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Switch Study of BMS-337039 in Schizophrenic Out-patients

Schizophrenia

Belgium, Spain, Italy, Austria, Germany, France, Czech Republic, United Kingdom, Greece, Hungary
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients

Schizophrenia

Turkey, Austria, Germany, South Africa, Sweden, Finland, Czech Republic, Poland, France, Hungary, United Kingdom, Switzerland
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in Patients With Acute Bipolar Mania

Bipolar Disorder

United States, Mexico, Peru, South Africa, Russian Federation, Croatia, Bulgaria
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.

Schizophrenia | Schizoaffective Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials

Schizophrenia

France, South Africa, Canada, Russian Federation, Poland, Czech Republic, Hungary, Croatia, Netherlands, Romania, United Kingdom
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type

Dementia, Alzheimer Type
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder

Bipolar Disorder Mania

Italy, Poland, Russian Federation, Turkey, South Africa, Austria, Hungary, France, Spain, Czech Republic, Germany, Greece, Romania
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Broad Effectiveness: Study With Aripiprazole

Schizophrenia | Schizoaffective Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in Subjects With Alcoholism

Alcoholism

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder | Psychotic Disorder | Body Weight Change

United States, Brazil, United Kingdom
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease

Parkinson's Disease | Psychoses

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Effect on Cognitive Function of a Treatment With Aripiprazole

Schizophrenia
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices

Schizophrenia

Belgium, France, Netherlands, Portugal, Spain
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices

Schizophrenia and Schizoaffective Disorder
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole Oral Acceptability Trial

Schizophrenia

United States
Duke University
Otsuka America Pharmaceutical

Terminated

A Pilot Dose-Response Biomarker Study of Brexpiprazole Treatment in PTSD

Post Traumatic Stress Disorder

United States
Northwestern University
Otsuka America Pharmaceutical

Completed

Effects of Tolvaptan in Healthy Adults

Healthy

United States
Otsuka America Pharmaceutical
Registrat-Mapi

Completed

Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia (HN Registry)

Euvolemic Hyponatremia | Hypervolemic Hyponatremia

United States, United Kingdom, Germany
University of Florida
Otsuka America Pharmaceutical

Completed

Tolvaptan for Ascites in Cirrhotic Patients

Cirrhosis | Ascites

United States
Bristol-Myers Squibb
Otsuka America Pharmaceutical

Completed

A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Bristol-Myers Squibb
Otsuka America Pharmaceutical

Completed

A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder

Major Depressive Disorder

United States
University of Chicago
Otsuka America Pharmaceutical

Completed

Brexpiprazole in Borderline Personality Disorder

Borderline Personality Disorder

United States
Vanguard Research Group
Otsuka America Pharmaceutical

Completed

Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics (PRELAPSE)

Schizophrenia

United States
NYU Langone Health
Otsuka America Pharmaceutical

Terminated

Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia

Hyponatremia

United States
Bristol-Myers Squibb
Otsuka America Pharmaceutical

Terminated

A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome

Schizophrenia | Metabolic Syndrome

France, Hungary, Spain, Czech Republic, Belgium, Germany, Greece, Switzerland, Turkey
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S; Otsuka America Pharmaceutical

Completed

Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia

Schizophrenia

United States, Croatia, Latvia
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S; Otsuka America Pharmaceutical

Completed

Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia

Schizophrenia

United States, Croatia, Latvia
University of Southern California
Otsuka America Pharmaceutical

Completed

Aquaresis Utility for Hyponatremic Acute Heart Failure Study (AQUA-AHF)

Heart Failure

United States
Caleb Nelson
Otsuka America Pharmaceutical

Completed

TCUPS- Tolvaptan Use in Cystinuria and Urolithiasis: A Pilot Study (TCUPS)

Cystinuria

United States
Gazda, Thomas D., M.D., PC
Otsuka America Pharmaceutical

Terminated

Aripiprazole, Abilify Maintena Collaborative Clinical Protocol (KISS)

Sexual Dysfunction

United States

Clinical Trials Sponsored by Otsuka America Pharmaceutical

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations